IRCT2015110424882N1 IRCT 2016-08-04 Kashan University of Medical Sciences, Dr Gholamali Hamidi Augmentation therapy comparison in refractory obsessive-compulsive disorder with Aripiprazole vs. Risperidone A survey about comparison of augmentation therapy in refractory obsessive-compulsive disorder patients; Aripiprazole vs. Risperidone 2013-04-21 anticipated 100 Complete https://irct.ir/trial/20919 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Obsessive-compulsive disorder. Intervention 1: In a group of patients in addition to SSRI drugs, Aripiprazole, production of sobhan corporation, begun with 2.5 mg and increased gradually to 10 mg, at the end of second week. All of patients were visited 8 times by psychiatrist. In cases of side effects incidence it was treated by lowering doses of drug and beginning more gradually, again or was taken necessary drugs (Propranolol, Lorazepam and Piperidine) to control side effects. Intervention 2: In other group also, in addition to SSRI drugs, Risperidone, production of sobhan corporation, begun with 1 mg and increased gradually to 2 mg, at the end of the first week. All of patients were visited 8 times by psychiatrist. In cases of side effects incidence it was treated by lowering doses of drug and beginning more gradually, again or was taken necessary drugs (Propranolol, Lorazepam and Piperidine) to control side effects.